NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of “Hold” from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received an average recommendation of “Hold” from the fourteen research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $11.8571.

A number of brokerages recently weighed in on NEO. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a report on Friday, March 27th. Piper Sandler lifted their price objective on shares of NeoGenomics from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, February 24th. Needham & Company LLC lifted their price objective on shares of NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Benchmark reiterated a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th. Finally, UBS Group reiterated a “hold” rating on shares of NeoGenomics in a report on Wednesday, February 18th.

Insiders Place Their Bets

In related news, COO Warren Stone sold 22,128 shares of NeoGenomics stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the sale, the chief operating officer owned 121,631 shares in the company, valued at $1,520,387.50. This trade represents a 15.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On NeoGenomics

Several large investors have recently modified their holdings of the business. First Light Asset Management LLC raised its holdings in shares of NeoGenomics by 1.1% in the 4th quarter. First Light Asset Management LLC now owns 10,035,063 shares of the medical research company’s stock valued at $118,012,000 after purchasing an additional 107,794 shares in the last quarter. Greenhouse Funds LLLP raised its holdings in shares of NeoGenomics by 10.6% in the 3rd quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company’s stock valued at $63,463,000 after purchasing an additional 789,510 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of NeoGenomics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock valued at $37,364,000 after purchasing an additional 44,733 shares in the last quarter. American Capital Management Inc. raised its holdings in shares of NeoGenomics by 120.9% in the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after purchasing an additional 1,283,390 shares in the last quarter. Finally, GW&K Investment Management LLC raised its holdings in shares of NeoGenomics by 7.5% in the 4th quarter. GW&K Investment Management LLC now owns 2,238,767 shares of the medical research company’s stock valued at $26,328,000 after purchasing an additional 155,882 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Price Performance

NEO stock opened at $8.00 on Tuesday. NeoGenomics has a 12 month low of $4.72 and a 12 month high of $13.74. The company has a current ratio of 4.26, a quick ratio of 3.94 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $9.20 and a 200 day moving average price of $10.48. The stock has a market cap of $1.04 billion, a PE ratio of -9.52 and a beta of 1.72.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The company had revenue of $190.17 million during the quarter, compared to analyst estimates of $188.25 million. During the same quarter last year, the business posted $0.04 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities research analysts anticipate that NeoGenomics will post -0.2 earnings per share for the current year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.